Diagnosis and treatment of psoriatic arthritis

被引:80
作者
Mease, P
Goffe, BS
机构
[1] Swedish Med Ctr, Med Ctr, Seattle Rheumatol Associates, Div Clin Res, Seattle, WA 98104 USA
[2] Univ Washington, Sch Med, Dept Dermatol, Seattle, WA 98195 USA
关键词
D O I
10.1016/j.jaad.2004.06.013
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriatic arthritis is a chronic, heterogeneous disease whose pathogenesis is unknown, although genetic, environmental, and immunologic factors play major roles. Psoriatic arthritis can follow an aggressive clinical Course, and differentiating it from other arthropathies is sometimes difficult. Diagnosis of psoriatic arthritis is based on history, physical examination, the usual absence of rheumatoid factor, and characteristic radiographic features. At least 40% of patients with psoriatic arthritis develop radiographically detectable joint destruction; therefore, proper diagnosis and early treatment can have a significant impact on disease course and outcome. Understanding the pathogenesis of psoriatic disease has led to the use of several biologic agents that work by modulating T-cell signaling or by inhibiting key cytokines involved in inflammation, such as tumor necrosis factor (TNF). TNF inhibitors have demonstrated excellent efficacy in resolving skin and joint disease in patients with psoriatic arthritis and have been shown to he safe agents in various inflammatory disorders. This article reviews the diagnostic and treatment challenges of psoriatic arthritis as they relate to pathogenesis and burden of disease.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 149 条
[1]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P241
[2]  
ALONSO JCT, 1991, BRIT J RHEUMATOL, V30, P245
[3]  
*AMG INC WYETH PHA, 2004, ENBR ET PACK INS
[4]  
Antoni C, 2003, ARTHRITIS RHEUM, V48, pS265
[5]  
Antoni C, 2002, ARTHRITIS RHEUM-US, V46, pS381
[6]  
Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS122
[7]   Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation [J].
Antoni, C ;
Dechant, C ;
Lorenz, PDHM ;
Wendler, J ;
Ogilvie, A ;
Lueftl, M ;
Kalden-Nemeth, D ;
Kalden, JR ;
Manger, B .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05) :506-512
[8]  
ANTONI C, 2003, 61 ANN M AM AC DERM
[9]  
ARNETT FC, 1991, RHEUM DIS CLIN N AM, V17, P59
[10]   Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study [J].
Baecklund, E ;
Ekbom, A ;
Sparén, P ;
Feltelius, N ;
Klareskog, L .
BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :180-181